Stuart Therapeutics

Stuart Therapeutics, Inc. is a clinical-stage drug platform company developing new therapies to treat a broad array of ocular conditions with a completely novel approach – healing through the restoration of disease-damaged collagen. The company’s PolyCol™ collagen mimetic peptide (CMP) technology platform is the first drug class to selectively target and heal specific areas of collagen damage implicated in trauma and disease where there is significant unmet need, including dry eye disease, corneal wound healing, glaucoma, dry AMD and myopia. The lead candidate on the PolyCol platform, ST-100, has demonstrated fast-acting resolution of dry eye signs and symptoms, signaling the opportunity to disrupt this $9.1 billion market and build an ocular surface franchise. The Stuart Therapeutics team includes executive leaders with extensive startup, early stage and large public company experience, as well as scientific advisors with deep expertise ophthalmic medicine and research. Headquartered in Stuart, Florida, Stuart Therapeutics is a privately held company with strong investor support, including InFocus Capital and the University of Wisconsin’s Alumni Research Foundation (WARF) and partnerships including Glaukos, Aju Pharm Co, Ora, Vanderbilt University and the University of Rochester. To learn more visit stuarttherapeutics.com and connect on LinkedIn.